 Connection
Matthew Daley to Drug-Related Side Effects and Adverse Reactions
This is a "connection" page, showing publications Matthew Daley has written about Drug-Related Side Effects and Adverse Reactions.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.257 |
|
|
|
-
Yih WK, Daley MF, Duffy J, Fireman B, McClure D, Nelson J, Qian L, Smith N, Vazquez-Benitez G, Weintraub E, Williams JTB, Xu S, Maro JC. A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink. Vaccine. 2023 01 16; 41(3):826-835.
Score: 0.173
-
Katherine Yih W, Daley MF, Duffy J, Fireman B, McClure D, Nelson J, Qian L, Smith N, Vazquez-Benitez G, Weintraub E, Williams JTB, Xu S, Maro JC. Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink. Vaccine. 2023 01 09; 41(2):460-466.
Score: 0.172
-
DeSilva M, Haapala J, Vazquez-Benitez G, Vesco KK, Daley MF, Getahun D, Zerbo O, Naleway A, Nelson JC, Williams JTB, Hambidge SJ, Boyce TG, Fuller CC, Lipkind HS, Weintraub E, McNeil MM, Kharbanda EO. Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy. N Engl J Med. 2022 07 14; 387(2):187-189.
Score: 0.167
-
Oliver SE, Wallace M, See I, Mbaeyi S, Godfrey M, Hadler SC, Jatlaoui TC, Twentyman E, Hughes MM, Rao AK, Fiore A, Su JR, Broder KR, Shimabukuro T, Lale A, Shay DK, Markowitz LE, Wharton M, Bell BP, Brooks O, McNally V, Lee GM, Talbot HK, Daley MF. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(3):90-95.
Score: 0.162
-
Wang SV, Stefanini K, Lewis E, Newcomer SR, Fireman B, Daley MF, Glanz JM, Duffy J, Weintraub E, Kulldorff M. Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event. Drug Saf. 2020 10; 43(10):1057-1065.
Score: 0.148
-
Newcomer SR, Kulldorff M, Xu S, Daley MF, Fireman B, Lewis E, Glanz JM. Bias from outcome misclassification in immunization schedule safety research. Pharmacoepidemiol Drug Saf. 2018 02; 27(2):221-228.
Score: 0.123
-
Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, Greene SK, Harrington T, Jackson LA, Klein NP, Tseng HF, Vellozzi C, Weintraub ES. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
Score: 0.106
-
Glanz JM, Newcomer SR, Daley MF, McClure DL, Baxter RP, Jackson ML, Naleway AL, Lugg MM, DeStefano F. Cumulative and episodic vaccine aluminum exposure in a population-based cohort of young children. Vaccine. 2015 Nov 27; 33(48):6736-44.
Score: 0.105
-
Hechter RC, Qian L, Sy LS, Greene SK, Weintraub ES, Naleway AL, Rowhani-Rahbar A, Donahue JG, Daley MF, Vazquez-Benitez G, Lugg MM, Jacobsen SJ. Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink project. Vaccine. 2013 Feb 04; 31(7):1080-5.
Score: 0.087
-
Kempe A, Daley MF, Crane LA, Barrow J, Chandramouli V, Beaty BL, Allred NJ, Berman S. Misperceptions regarding influenza vaccine safety for individuals with chronic medical illness. Prev Med. 2007 Jul; 45(1):80-2.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|